Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + cyclophosphamide + docetaxel
- Development stage
- Phase 3
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
A combination chemotherapy regimen consisting of bevacizumab (a humanized monoclonal antibody targeting VEGF), cyclophosphamide (an alkylating agent), and docetaxel (a taxane). This combination targets cancer through multiple mechanisms: inhibiting angiogenesis, damaging DNA, and disrupting microtubule function during cell division. Bevacizumab targets vascular endothelial growth factor (VEGF) to inhibit angiogenesis. Cyclophosphamide is an alkylating agent that damages DNA and interferes with cell replication; in lower doses, it also has immunomodulatory effects. Docetaxel disrupts microtubule function, preventing cell division.
02
Targets
Beyond the preview
Go deeper on bevacizumab + cyclophosphamide + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + cyclophosphamide + docetaxel.